Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Naringin, a flavonoid found predominantly in grapefruit and other citrus fruits, has been studied in preclinical models for its potential benefits in non-alcoholic fatty liver disease (NAFLD). Animal studies suggest that naringin may exert hepatoprotective effects by reducing hepatic lipid accumulation, modulating oxidative stress, and improving insulin sensitivity. These effects are thought to be mediated through several mechanisms, such as the activation of AMP-activated protein kinase (AMPK), reduction of inflammatory cytokines, and enhancement of antioxidant enzyme activities. For example, rodent studies have shown that naringin supplementation can decrease liver fat content and improve markers of liver injury in high-fat diet-induced models of NAFLD. However, despite these promising preclinical findings, robust human clinical trial data are lacking. Most evidence for naringin’s effect on fatty liver disease comes from animal experiments or in vitro studies, and there are currently no large-scale, well-controlled human studies that directly demonstrate its efficacy for this indication. While naringin is not a traditional remedy specifically for fatty liver disease, its use is increasingly explored based on its mechanistic plausibility and results from laboratory research. In summary, naringin’s use for fatty liver disease is supported by early-stage scientific research, particularly in animal models, but clinical evidence in humans is currently insufficient. As such, naringin should not be considered a proven therapy for fatty liver disease, and further human studies are needed to validate its potential benefits.

More about naringin
More about Fatty Liver Disease

Other ingredients used for Fatty Liver Disease

Other health conditions supported by naringin

Products containing naringin

Pure Encapsulations Acerola/Flavonoid